Literature DB >> 24180338

Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load.

José Peña1, Norman G Jones, Stephanie Bousheri, David R Bangsberg, Huyen Cao.   

Abstract

Mechanisms leading to the observed immune dysregulation in chronic HIV infection are not well understood. The MHC-II class ligand, lymphocyte activation gene-3 (LAG-3, CD223), has been implicated in the complex regulation mechanism of immune functions. In this study, we describe a new population of HIV-specific CD8(+) T cells expressing LAG-3. These LAG-3(+)CD8(+) T cells do not display immunophenotypic patterns traditionally attributed to regulatory T cells. The LAG3(+)CD8(+) T cells are CCR7(+),CD127(-), and display heterogeneous surface expressions of CD45RA and CD25. Interestingly, HIV-specific LAG-3(+)CD8(+) T cells do not substantially express CTLA-4 and LAG-3 expression does not correlate with interleukin (IL)-10 or tumor growth factor (TGF)-β production. In addition, HIV-specific LAG3(+)CD8(+) T cells do not produce interferon (IFN-γ) or express CD107a. The frequency of HIV-specific LAG3(+)CD8(+) T cells negative correlated with plasma viral load. Our study introduces a new population of HIV-specific CD8(+) T cells and proposes additional mechanisms of immune regulation in chronic HIV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24180338      PMCID: PMC4046223          DOI: 10.1089/aid.2012.0195

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  43 in total

1.  HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis.

Authors:  Mohamed Elrefaei; Banson Barugahare; Francis Ssali; Peter Mugyenyi; Huyen Cao
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

2.  Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals.

Authors:  Mirko Paiardini; Barbara Cervasi; Helmut Albrecht; Alagarraju Muthukumar; Richard Dunham; Shari Gordon; Henry Radziewicz; Giuseppe Piedimonte; Mauro Magnani; Maria Montroni; Susan M Kaech; Amy Weintrob; John D Altman; Donald L Sodora; Mark B Feinberg; Guido Silvestri
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

3.  C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease.

Authors:  D Peritt; D A Sesok-Pizzini; R Schretzenmair; R R Macgregor; N M Valiante; X Tu; G Trinchieri; M Kamoun
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

4.  The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.

Authors:  Laëtitia Maçon-Lemaître; Frédéric Triebel
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

5.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

6.  Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.

Authors:  Malgorzata Kisielow; Jan Kisielow; Giuseppina Capoferri-Sollami; Klaus Karjalainen
Journal:  Eur J Immunol       Date:  2005-07       Impact factor: 5.532

7.  Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).

Authors:  Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

8.  CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection.

Authors:  S Zanussi; C Simonelli; M D'Andrea; C Caffau; M Clerici; U Tirelli; P DePaoli
Journal:  Clin Exp Immunol       Date:  1996-08       Impact factor: 4.330

9.  CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.

Authors:  S Hannier; M Tournier; G Bismuth; F Triebel
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

10.  Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II.

Authors:  D Bruniquel; N Borie; S Hannier; F Triebel
Journal:  Immunogenetics       Date:  1998-07       Impact factor: 2.846

View more
  5 in total

Review 1.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

2.  Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment.

Authors:  Jennifer A Juno; Andrew T Stalker; Jillian Lm Waruk; Julius Oyugi; Makobu Kimani; Francis A Plummer; Joshua Kimani; Keith R Fowke
Journal:  Retrovirology       Date:  2015-02-13       Impact factor: 4.602

3.  TCR affinity associated with functional differences between dominant and subdominant SIV epitope-specific CD8+ T cells in Mamu-A*01+ rhesus monkeys.

Authors:  Christa E Osuna; Ana Maria Gonzalez; Hsun-Hsien Chang; Amy Shi Hung; Elizabeth Ehlinger; Kara Anasti; S Munir Alam; Norman L Letvin
Journal:  PLoS Pathog       Date:  2014-04-17       Impact factor: 6.823

Review 4.  Lymphocyte-activation gene-3, an important immune checkpoint in cancer.

Authors:  Yayi He; Christopher J Rivard; Leslie Rozeboom; Hui Yu; Kim Ellison; Ashley Kowalewski; Caicun Zhou; Fred R Hirsch
Journal:  Cancer Sci       Date:  2016-08-25       Impact factor: 6.716

5.  Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells.

Authors:  Nina C Sabins; Benjamin C Harman; Linda R Barone; Shixue Shen; Sandra Santulli-Marotto
Journal:  Front Immunol       Date:  2016-06-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.